Compugen
Health Care · USD
Price
$2.58
Cap
$244M
Earnings
3/3 beat
30d Trend
+4%
Near 52-week highs — limited upside before resistance
Target range: $4 – $6 (consensus: $4.67)
Consensus: Strong Buy
Earnings history
Q4 2025
BEAT
0.6 vs 0.05
Q3 2025
BEAT
-0.07 vs -0.09
Q2 2025
BEAT
-0.08 vs -0.09
Key macro factors
Central Banks shifting to 'Higher for Longer' rates, increasing the cost of capital and impacting investor appetite for growth-oriented biotech companies like Compugen. [context]
The ongoing Q1 2026 earnings season, where overall market sentiment and sector-specific results can influence investor confidence in biotech stocks. [context]
Geopolitical tensions and events such as the Iran War Escalation and Strait of Hormuz closure, which could lead to sustained oil price volatility and increased operational costs. [context]
Compugen Ltd. is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.